Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Karuna Therapeutics, Inc. - Common Stock (NQ:KRTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 326.49 (1)
Ask (Size) 329.94 (1)
Prev. Close 329.83
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 37,443,954
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect
Hedge funds are shifting towards stability and value by favoring the health care sector over booming tech stocks. 
Via Benzinga
Karuna Therapeutics: Q4 Earnings Insights
Via Benzinga

Performance

More News

Read More
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
From Karuna Therapeutics, Inc.
Via Business Wire
Mental Health Mavericks: 3 Stocks Changing the Game
Via InvestorPlace
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Via Benzinga
Mizuho Downgrades Karuna Therapeutics: Here's What You Need To Know
Via Benzinga
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
From Kahn Swick & Foti, LLC
Via Business Wire
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc. (NYSE – CTLT), Everbridge, Inc. (Nasdaq – EVBG), Slam Corp. (Nasdaq – SLAM), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)
From Brodsky & Smith LLC
Via GlobeNewswire
ABBV: This Top Biotech Just Went On A Buying Spree
Via Talk Markets
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)
From Brodsky & Smith LLC
Via GlobeNewswire
Bullish Continuation In '24? 3 Market Areas To Watch
Via Talk Markets
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
Via Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Via Investor's Business Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
From Kahn Swick & Foti, LLC
Via Business Wire
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Via MarketBeat
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst
Via Benzinga
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
Via Investor's Business Daily
Why Is RayzeBio (RYZB) Stock Up 100% Today?
Via InvestorPlace

Frequently Asked Questions

Is Karuna Therapeutics, Inc. - Common Stock publicly traded?
Yes, Karuna Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Karuna Therapeutics, Inc. - Common Stock trade on?
Karuna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Karuna Therapeutics, Inc. - Common Stock?
The ticker symbol for Karuna Therapeutics, Inc. - Common Stock is KRTX on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.